Rockeby OTC approval in Europe for rapid candida test 09:14, Monday, 2 April 2007
Sydney - Monday - April 2: (RWE Australian Business News) - Singapore-based diagnostics group Rockeby Biomed Ltd (ASX code: RBY) has received European Over-The-Counter (OTC) approval - 'CE OTC Mark' - for its flagship product, CanDia5, for home or self-testing in Europe. The CanDia5 Rapid Candida Test is used for the accurate detection of Vulvovaginal Candidiasis (VVC) within six minutes. VVC, which is also known as Vaginal Thrush, Monilial or yeast infection, is a common cause of vaginal irritation. The condition affects up to 75 per cent of all women during their reproductive years (age 15 to 45). Between 5% and 10% of healthy women of reproductive age may suffer from recurrent VVC, which is defined as four to five infections per year. Symptoms of VVC are non-specific and neither self-diagnosis, nor diagnosis by a physician, is reliable without laboratory confirmation. Incorrect diagnosis can result in the overuse of topical antifungal agents, with the subsequent risk of contact and irritant vulvar dermatitis. Obtaining the 'CE OTC Mark' for CanDia5 means that it can be sold to consumers directly over the counter in any setting such as pharmacies, and supermarkets in Europe, allowing Rockeby to promote and market the product to a potential market of 15 million female users in Europe for home or self-testing of VVC.
RBY Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
